시장보고서
상품코드
1166012

마우스 모델 제작 시장 : 세계 산업 분석, 규모, 점유율, 성장률, 동향, 예측(2022-2031년)

Mice Model Generation Market (Technology: CRISPR Knockout, CRISPR Knockin, Random Insertions, Large & Targeted Insertions, ES Cell Modification, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

발행일: | 리서치사: Transparency Market Research | 페이지 정보: 영문 230 Pages | 배송안내 : 2-10일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 마우스 모델 제작 시장에 대해 조사했으며, 시장 개요와 2022-2031년의 예측, 기술별, 최종사용자별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 서문

제2장 전제와 조사 방법

제3장 주요 요약 : 세계의 마우스 모델 제작 시장

제4장 시장 개요

  • 서론
  • 개요
  • 시장 역학
  • 세계의 마우스 모델 제작 시장 분석과 예측, 2017-2031년

제5장 주요 인사이트

제6장 세계의 마우스 모델 제작 시장 분석과 예측, 기술별

  • 서론과 정의
  • 주요 조사 결과/개발
  • 기술별 시장 가치 예측, 2017-2031년
    • CRISPR 녹아웃
    • CRISPR 녹인
    • 랜덤 삽입
    • 대형, 표적 삽입
    • ES 세포 개변(상동 재조합)
    • 기타
  • 기술별 시장의 매력 분석

제7장 세계의 마우스 모델 제작 시장 분석과 예측, 최종사용자별

  • 서론과 정의
  • 주요 조사 결과/개발
  • 시장 가치 예측, 최종사용자별, 2017-2031년
    • 제약회사
    • 바이오테크놀러지 기업
    • 학술·연구 시설
    • 수탁 연구·제조 기관
  • 최종사용자별 시장의 매력 분석

제8장 세계의 마우스 모델 제작 시장 분석과 예측, 지역별

  • 주요 조사 결과
  • 지역별 시장 가치 예측
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • 중동·아프리카
  • 지역별 시장의 매력 분석

제9장 북미의 마우스 모델 제작 시장 분석과 예측

제10장 유럽의 마우스 모델 제작 시장 분석과 예측

제11장 아시아태평양의 마우스 모델 제작 시장 분석과 예측

제12장 라틴아메리카의 마우스 모델 제작 시장 분석과 예측

제13장 중동·아프리카의 마우스 모델 제작 시장 분석과 예측

제14장 경쟁 구도

  • 시장 참여 기업 - 경쟁 매트릭스(층 및 기업 규모별)
  • 시장 점유율 분석, 기업별, 2021년
  • 기업 개요
    • Biocytogen
    • Charles River Laboratories
    • Cyagen Biosciences
    • Gempharmatech
    • genOway
    • ingenious targeting laboratory
    • Merck KGaA
    • Ozgene Pty Ltd.
    • Taconic Biosciences, Inc.
    • PolyGene AG
    • The Jackson Laboratory
    • Yale School of Medicine
    • University of North Carolina
    • University of Nebraska Medical Center
    • Monash University
    • UMass Chan Medical School
    • University of Bonn
    • Columbia University
    • The University of Arizona
    • Hadassah BrainLabs
    • The Weizmann Institute of Science
    • The Hebrew University of Jerusalem
    • The Technion-Israel Institute of Technology
KSA 22.12.15

TMR's report on the global mice model generation market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global mice model generation market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global mice model generation market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the mice model generation market.

The report delves into the competitive landscape of the global mice model generation market. Key players operating in the global mice model generation market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global mice model generation market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Mice Model Generation Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Mice Model Generation Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Global Genetically Engineered Mouse Model Overview
  • 5.2. Regulatory Scenario by Region/globally
  • 5.3. Technological Advancements
  • 5.4. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)
  • 5.5. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Mice Model Generation Market Analysis and Forecast, by Technology

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Technology, 2017-2031
    • 6.3.1. CRISPR Knockout
    • 6.3.2. CRISPR Knockin
    • 6.3.3. Random Insertions
    • 6.3.4. Large, Targeted Insertions
    • 6.3.5. ES Cell Modification (homologous recombination)
    • 6.3.6. Others
  • 6.4. Market Attractiveness Analysis, by Technology

7. Global Mice Model Generation Market Analysis and Forecast, by End-user

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by End-user, 2017-2031
    • 7.3.1. Pharmaceutical Companies
    • 7.3.2. Biotechnology Companies
    • 7.3.3. Academic & Research Facilities
    • 7.3.4. Contract Research & Manufacturing Organizations
  • 7.4. Market Attractiveness Analysis, by End-user

8. Global Mice Model Generation Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness Analysis, by Region

9. North America Mice Model Generation Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Technology, 2017-2031
    • 9.2.1. CRISPR Knockout
    • 9.2.2. CRISPR Knockin
    • 9.2.3. Random Insertions
    • 9.2.4. Large, Targeted Insertions
    • 9.2.5. ES Cell Modification (homologous recombination)
    • 9.2.6. Others
  • 9.3. Market Value Forecast, by End-user, 2017-2031
    • 9.3.1. Pharmaceutical Companies
    • 9.3.2. Biotechnology Companies
    • 9.3.3. Academic & Research Facilities
    • 9.3.4. Contract Research & Manufacturing Organizations
  • 9.4. Market Value Forecast, by End-user by Technology, 2017-2031
    • 9.4.1. Pharmaceutical Companies
      • 9.4.1.1. CRISPR Knockout
      • 9.4.1.2. CRISPR Knockin
      • 9.4.1.3. Random Insertions
      • 9.4.1.4. Large, Targeted Insertions
      • 9.4.1.5. ES Cell Modification (homologous recombination)
      • 9.4.1.6. Others
    • 9.4.2. Biotechnology Companies
      • 9.4.2.1. CRISPR Knockout
      • 9.4.2.2. CRISPR Knockin
      • 9.4.2.3. Random Insertions
      • 9.4.2.4. Large, Targeted Insertions
      • 9.4.2.5. ES Cell Modification (homologous recombination)
      • 9.4.2.6. Others
    • 9.4.3. Academic & Research Facilities
      • 9.4.3.1. CRISPR Knockout
      • 9.4.3.2. CRISPR Knockin
      • 9.4.3.3. Random Insertions
      • 9.4.3.4. Large, Targeted Insertions
      • 9.4.3.5. ES Cell Modification (homologous recombination)
      • 9.4.3.6. Others
    • 9.4.4. Contract Research & Manufacturing Organizations
      • 9.4.4.1. CRISPR Knockout
      • 9.4.4.2. CRISPR Knockin
      • 9.4.4.3. Random Insertions
      • 9.4.4.4. Large, Targeted Insertions
      • 9.4.4.5. ES Cell Modification (homologous recombination)
      • 9.4.4.6. Others
  • 9.5. Market Value Forecast, by Country, 2017-2031
    • 9.5.1. U.S.
    • 9.5.2. Canada
  • 9.6. Market Attractiveness Analysis
    • 9.6.1. By Technology
    • 9.6.2. By End-user
    • 9.6.3. By End-user by Technology
    • 9.6.4. By Country

10. Europe Mice Model Generation Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Technology, 2017-2031
    • 10.2.1. CRISPR Knockout
    • 10.2.2. CRISPR Knockin
    • 10.2.3. Random Insertions
    • 10.2.4. Large, Targeted Insertions
    • 10.2.5. ES Cell Modification (homologous recombination)
    • 10.2.6. Others
  • 10.3. Market Value Forecast, by End-user, 2017-2031
    • 10.3.1. Pharmaceutical Companies
    • 10.3.2. Biotechnology Companies
    • 10.3.3. Academic & Research Facilities
    • 10.3.4. Contract Research & Manufacturing Organizations
  • 10.4. Market Value Forecast, by End-user by Technology, 2017-2031
    • 10.4.1. Pharmaceutical Companies
      • 10.4.1.1. CRISPR Knockout
      • 10.4.1.2. CRISPR Knockin
      • 10.4.1.3. Random Insertions
      • 10.4.1.4. Large, Targeted Insertions
      • 10.4.1.5. ES Cell Modification (homologous recombination)
      • 10.4.1.6. Others
    • 10.4.2. Biotechnology Companies
      • 10.4.2.1. CRISPR Knockout
      • 10.4.2.2. CRISPR Knockin
      • 10.4.2.3. Random Insertions
      • 10.4.2.4. Large, Targeted Insertions
      • 10.4.2.5. ES Cell Modification (homologous recombination)
      • 10.4.2.6. Others
    • 10.4.3. Academic & Research Facilities
      • 10.4.3.1. CRISPR Knockout
      • 10.4.3.2. CRISPR Knockin
      • 10.4.3.3. Random Insertions
      • 10.4.3.4. Large, Targeted Insertions
      • 10.4.3.5. ES Cell Modification (homologous recombination)
      • 10.4.3.6. Others
    • 10.4.4. Contract Research & Manufacturing Organizations
      • 10.4.4.1. CRISPR Knockout
      • 10.4.4.2. CRISPR Knockin
      • 10.4.4.3. Random Insertions
      • 10.4.4.4. Large, Targeted Insertions
      • 10.4.4.5. ES Cell Modification (homologous recombination)
      • 10.4.4.6. Others
  • 10.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.5.1. Germany
    • 10.5.2. U.K.
    • 10.5.3. France
    • 10.5.4. Spain
    • 10.5.5. Italy
    • 10.5.6. Rest of Europe
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Technology
    • 10.6.2. By End-user
    • 10.6.3. By End-user by Technology
    • 10.6.4. By Country/Sub-region

11. Asia Pacific Mice Model Generation Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Technology, 2017-2031
    • 11.2.1. CRISPR Knockout
    • 11.2.2. CRISPR Knockin
    • 11.2.3. Random Insertions
    • 11.2.4. Large, Targeted Insertions
    • 11.2.5. ES Cell Modification (homologous recombination)
    • 11.2.6. Others
  • 11.3. Market Value Forecast, by End-user, 2017-2031
    • 11.3.1. Pharmaceutical Companies
    • 11.3.2. Biotechnology Companies
    • 11.3.3. Academic & Research Facilities
    • 11.3.4. Contract Research & Manufacturing Organizations
  • 11.4. Market Value Forecast, by End-user by Technology, 2017-2031
    • 11.4.1. Pharmaceutical Companies
      • 11.4.1.1. CRISPR Knockout
      • 11.4.1.2. CRISPR Knockin
      • 11.4.1.3. Random Insertions
      • 11.4.1.4. Large, Targeted Insertions
      • 11.4.1.5. ES Cell Modification (homologous recombination)
      • 11.4.1.6. Others
    • 11.4.2. Biotechnology Companies
      • 11.4.2.1. CRISPR Knockout
      • 11.4.2.2. CRISPR Knockin
      • 11.4.2.3. Random Insertions
      • 11.4.2.4. Large, Targeted Insertions
      • 11.4.2.5. ES Cell Modification (homologous recombination)
      • 11.4.2.6. Others
    • 11.4.3. Academic & Research Facilities
      • 11.4.3.1. CRISPR Knockout
      • 11.4.3.2. CRISPR Knockin
      • 11.4.3.3. Random Insertions
      • 11.4.3.4. Large, Targeted Insertions
      • 11.4.3.5. ES Cell Modification (homologous recombination)
      • 11.4.3.6. Others
    • 11.4.4. Contract Research & Manufacturing Organizations
      • 11.4.4.1. CRISPR Knockout
      • 11.4.4.2. CRISPR Knockin
      • 11.4.4.3. Random Insertions
      • 11.4.4.4. Large, Targeted Insertions
      • 11.4.4.5. ES Cell Modification (homologous recombination)
      • 11.4.4.6. Others
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. China
    • 11.5.2. Japan
    • 11.5.3. India
    • 11.5.4. Australia & New Zealand
    • 11.5.5. Rest of Asia Pacific
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Technology
    • 11.6.2. By End-user
    • 11.6.3. By End-user by Technology
    • 11.6.4. By Country/Sub-region

12. Latin America Mice Model Generation Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Technology, 2017-2031
    • 12.2.1. CRISPR Knockout
    • 12.2.2. CRISPR Knockin
    • 12.2.3. Random Insertions
    • 12.2.4. Large, Targeted Insertions
    • 12.2.5. ES Cell Modification (homologous recombination)
    • 12.2.6. Others
  • 12.3. Market Value Forecast, by End-user, 2017-2031
    • 12.3.1. Pharmaceutical Companies
    • 12.3.2. Biotechnology Companies
    • 12.3.3. Academic & Research Facilities
    • 12.3.4. Contract Research & Manufacturing Organizations
  • 12.4. Market Value Forecast, by End-user by Technology, 2017-2031
    • 12.4.1. Pharmaceutical Companies
      • 12.4.1.1. CRISPR Knockout
      • 12.4.1.2. CRISPR Knockin
      • 12.4.1.3. Random Insertions
      • 12.4.1.4. Large, Targeted Insertions
      • 12.4.1.5. ES Cell Modification (homologous recombination)
      • 12.4.1.6. Others
    • 12.4.2. Biotechnology Companies
      • 12.4.2.1. CRISPR Knockout
      • 12.4.2.2. CRISPR Knockin
      • 12.4.2.3. Random Insertions
      • 12.4.2.4. Large, Targeted Insertions
      • 12.4.2.5. ES Cell Modification (homologous recombination)
      • 12.4.2.6. Others
    • 12.4.3. Academic & Research Facilities
      • 12.4.3.1. CRISPR Knockout
      • 12.4.3.2. CRISPR Knockin
      • 12.4.3.3. Random Insertions
      • 12.4.3.4. Large, Targeted Insertions
      • 12.4.3.5. ES Cell Modification (homologous recombination)
      • 12.4.3.6. Others
    • 12.4.4. Contract Research & Manufacturing Organizations
      • 12.4.4.1. CRISPR Knockout
      • 12.4.4.2. CRISPR Knockin
      • 12.4.4.3. Random Insertions
      • 12.4.4.4. Large, Targeted Insertions
      • 12.4.4.5. ES Cell Modification (homologous recombination)
      • 12.4.4.6. Others
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. Brazil
    • 12.5.2. Mexico
    • 12.5.3. Rest of Latin America
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Technology
    • 12.6.2. By End-user
    • 12.6.3. By End-user by Technology
    • 12.6.4. By Country/Sub-region

13. Middle East & Africa Mice Model Generation Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Technology, 2017-2031
    • 13.2.1. CRISPR Knockout
    • 13.2.2. CRISPR Knockin
    • 13.2.3. Random Insertions
    • 13.2.4. Large, Targeted Insertions
    • 13.2.5. ES Cell Modification (homologous recombination)
    • 13.2.6. Others
  • 13.3. Market Value Forecast, by End-user, 2017-2031
    • 13.3.1. Pharmaceutical Companies
    • 13.3.2. Biotechnology Companies
    • 13.3.3. Academic & Research Facilities
    • 13.3.4. Contract Research & Manufacturing Organizations
  • 13.4. Market Value Forecast, by End-user by Technology, 2017-2031
    • 13.4.1. Pharmaceutical Companies
      • 13.4.1.1. CRISPR Knockout
      • 13.4.1.2. CRISPR Knockin
      • 13.4.1.3. Random Insertions
      • 13.4.1.4. Large, Targeted Insertions
      • 13.4.1.5. ES Cell Modification (homologous recombination)
      • 13.4.1.6. Others
    • 13.4.2. Biotechnology Companies
      • 13.4.2.1. CRISPR Knockout
      • 13.4.2.2. CRISPR Knockin
      • 13.4.2.3. Random Insertions
      • 13.4.2.4. Large, Targeted Insertions
      • 13.4.2.5. ES Cell Modification (homologous recombination)
      • 13.4.2.6. Others
    • 13.4.3. Academic & Research Facilities
      • 13.4.3.1. CRISPR Knockout
      • 13.4.3.2. CRISPR Knockin
      • 13.4.3.3. Random Insertions
      • 13.4.3.4. Large, Targeted Insertions
      • 13.4.3.5. ES Cell Modification (homologous recombination)
      • 13.4.3.6. Others
    • 13.4.4. Contract Research & Manufacturing Organizations
      • 13.4.4.1. CRISPR Knockout
      • 13.4.4.2. CRISPR Knockin
      • 13.4.4.3. Random Insertions
      • 13.4.4.4. Large, Targeted Insertions
      • 13.4.4.5. ES Cell Modification (homologous recombination)
      • 13.4.4.6. Others
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. GCC Countries
    • 13.5.2. South Africa
    • 13.5.3. Rest of Middle East & Africa
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Technology
    • 13.6.2. By End-user
    • 13.6.3. By End-user by Technology
    • 13.6.4. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (by tier and size of companies)
  • 14.2. Market Share Analysis, by Company, 2021
    • 14.2.1. Global
    • 14.2.2. North America
    • 14.2.3. Europe
    • 14.2.4. By Asia Pacific
    • 14.2.5. By Latin America
    • 14.2.6. By Middle East & Africa
  • 14.3. Company Profiles
    • 14.3.1. Biocytogen
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. SWOT Analysis
      • 14.3.1.4. Strategic Overview
    • 14.3.2. Charles River Laboratories
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. SWOT Analysis
      • 14.3.2.4. Strategic Overview
    • 14.3.3. Cyagen Biosciences
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. SWOT Analysis
      • 14.3.3.4. Strategic Overview
    • 14.3.4. Gempharmatech
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. SWOT Analysis
      • 14.3.4.4. Strategic Overview
    • 14.3.5. genOway
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. SWOT Analysis
      • 14.3.5.4. Strategic Overview
    • 14.3.6. ingenious targeting laboratory
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. SWOT Analysis
      • 14.3.6.4. Strategic Overview
    • 14.3.7. Merck KGaA
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. SWOT Analysis
      • 14.3.7.4. Strategic Overview
    • 14.3.8. Ozgene Pty Ltd.
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. SWOT Analysis
      • 14.3.8.4. Strategic Overview
    • 14.3.9. Taconic Biosciences, Inc.
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. SWOT Analysis
      • 14.3.9.4. Strategic Overview
    • 14.3.10. PolyGene AG
      • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.10.2. Product Portfolio
      • 14.3.10.3. SWOT Analysis
      • 14.3.10.4. Strategic Overview
    • 14.3.11. The Jackson Laboratory
      • 14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.11.2. Product Portfolio
      • 14.3.11.3. SWOT Analysis
      • 14.3.11.4. Strategic Overview
    • 14.3.12. Yale School of Medicine
      • 14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.12.2. Product Portfolio
      • 14.3.12.3. SWOT Analysis
      • 14.3.12.4. Strategic Overview
    • 14.3.13. University of North Carolina
      • 14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.13.2. Product Portfolio
      • 14.3.13.3. SWOT Analysis
      • 14.3.13.4. Strategic Overview
    • 14.3.14. University of Nebraska Medical Center
      • 14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.14.2. Product Portfolio
      • 14.3.14.3. SWOT Analysis
      • 14.3.14.4. Strategic Overview
    • 14.3.15. Monash University
      • 14.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.15.2. Product Portfolio
      • 14.3.15.3. SWOT Analysis
      • 14.3.15.4. Strategic Overview
    • 14.3.16. UMass Chan Medical School
      • 14.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.16.2. Product Portfolio
      • 14.3.16.3. SWOT Analysis
      • 14.3.16.4. Strategic Overview
    • 14.3.17. University of Bonn
      • 14.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.17.2. Product Portfolio
      • 14.3.17.3. SWOT Analysis
      • 14.3.17.4. Strategic Overview
    • 14.3.18. Columbia University
      • 14.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.18.2. Product Portfolio
      • 14.3.18.3. SWOT Analysis
      • 14.3.18.4. Strategic Overview
    • 14.3.19. The University of Arizona
      • 14.3.19.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.19.2. Product Portfolio
      • 14.3.19.3. SWOT Analysis
      • 14.3.19.4. Strategic Overview
    • 14.3.20. Hadassah BrainLabs
      • 14.3.20.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.20.2. Product Portfolio
      • 14.3.20.3. SWOT Analysis
      • 14.3.20.4. Strategic Overview
    • 14.3.21. The Weizmann Institute of Science
      • 14.3.21.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.21.2. Product Portfolio
      • 14.3.21.3. SWOT Analysis
      • 14.3.21.4. Strategic Overview
    • 14.3.22. The Hebrew University of Jerusalem
      • 14.3.22.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.22.2. Product Portfolio
      • 14.3.22.3. SWOT Analysis
      • 14.3.22.4. Strategic Overview
    • 14.3.23. The Technion - Israel Institute of Technology
      • 14.3.23.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.23.2. Product Portfolio
      • 14.3.23.3. SWOT Analysis
      • 14.3.23.4. Strategic Overview
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제